TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04890327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based family health history tool
Description: Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
Study: NCT01960023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
Study: NCT02662114

Intervention type: OTHER
Intervention: No treatment given
Description: Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
Study: NCT01960023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study.
Study: NCT01711463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once daily for 7 days in each treatment period.
Study: NCT03413579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab ( h-R3)
Description: Humanized monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01216644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1, i.v., every 2 weeks
Study: NCT00567918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Ophthalmic suspension
Study: NCT02608749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Description: Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower extremity exercise (LEE)
Description: Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
Study: NCT01216644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50 mg/m2, d1, i.v., every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 60 mg/m², d1, i.v., every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 200 mg/m², d1-d21, i.v., every 3 weeks
Study: NCT02036983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block (TAP BLOCK)
Description: Ultrasound guided TAP block with local anesthetics and dexamethasone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instillation of surgical site with local anesthetic.
Description: Instillation of surgical site with local anesthetics and dexamethasone.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Opioid IV medications (Control)
Description: Standard anesthetic technique.
Study: NCT02411968

Intervention type: OTHER
Intervention: 111In-Girentuximab DOTA SPECT
Study: NCT00494559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Actos 15mg once a day before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug with the same appearance as actos
Study: NCT02635334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10 mg orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04448015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care
Description: University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
Study: NCT04014543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastronomy
Description: to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times.
Study: NCT00815191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a forced-air warming cover
Description: A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vital HEAT (vH2) Temperature Management System
Description: The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
Study: NCT03527290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiometabolic Health Diet
Description: The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
Study: NCT03839836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backpack child's body weight
Description: Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
Study: NCT03192033

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial closure to ensure hemostasis at femoral artery puncture points
Description: Arterial closure devices used: Proglide® (Abbott)

Intervention type: DEVICE
Group type: OTHER
Intervention: Proglide® (Abbott)
Description: Arterial closure device used: Proglide® (Abbott)

Intervention type: DEVICE
Group type: OTHER
Intervention: Femoseal® (Terumo)
Description: Arterial closure device used: Femoseal® (Terumo)

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial closure to ensure hemostasis at femoral artery puncture points
Description: Arterial closure device used: Femoseal® (Terumo)
Study: NCT02737995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose infusion
Description: Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
Study: NCT04609930

Intervention type: DRUG
Intervention: Anti-PD-1 or anti-PD-L1
Description: Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
Study: NCT04433559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 1,5 mg oral tablets
Description: Use of tadalafil in the treatment of FSIAD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablets
Description: Use of placebo in control group
Study: NCT03947528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fed condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fed condition
Study: NCT00215514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
Study: NCT00613080

Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: 1650 mg/m\^2/day orally 5 days/week during radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection
Description: All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX
Description: Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1.
Study: NCT02226549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study: NCT03665129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5401 and Durvalumab
Description: IPH5401 and durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5401 and Durvalumab
Description: IPH5401 and durvalumab
Study: NCT02226549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDV
Description: VDV 80 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDV
Description: VDV 80 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01615601

Intervention type: DRUG
Intervention: darunavir (PREZISTA)
Description: Form = tablet, route = oral, Units = mg, number = 800 administered once daily

Intervention type: DRUG
Intervention: etravirine (INTELENCE)
Description: Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily

Intervention type: DRUG
Intervention: ritonavir
Description: Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily

Intervention type: DRUG
Intervention: Other antiretroviral medications
Description: Given as per Canadian Product Monograph
Study: NCT02608749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home care (HC)
Description: Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
Study: NCT03130842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual alprazolam
Description: Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
Study: NCT01522755

Intervention type: DEVICE
Intervention: Pacing system implant with the CapsureFix MRI pacing lead model 5086
Description: Pacing system implant with the CapsureFix MRI pacing lead model 5086
Study: NCT03221244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Treatment
Description: Distractors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Active Control
Description: No distractors
Study: NCT02015065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
Study: NCT00483379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: intravenous infusion
Study: NCT04923204

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomic-testing with NEUROPHARMAGEN
Description: This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information.
Study: NCT01910090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET
Description: MULTI-LAYER TABLET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTADYS® 100 mg, PEPCID® 20 mg
Description: ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
Study: NCT00795938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Oral Tablet With Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet With Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
Study: NCT02008981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma longa
Description: Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angelica sinensis
Description: Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siwu Tang
Description: TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study: NCT02597127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
Study: NCT03216486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Description: IV administration of BPS804 in 5% Dextrose solution
Study: NCT03571165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care - In Care
Description: Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
Study: NCT00787202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP- 690 550
Description: Administration via oral route twice daily for the duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP- 690 550
Description: Administration via oral route twice daily for the duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP- 690 550
Description: Administration via oral route twice daily for the duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP- 690 550
Description: Administration via oral route twice daily for the duration of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administration via oral route twice daily for the duration of treatment
Study: NCT01442064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
Study: NCT01268917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: aspirin 100mg daily until the surgery day

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: aspirin
Description: aspirin is stopped 5-7 days before operation
Study: NCT02316210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation